Schizophrenia Therapeutics Market

Schizophrenia therapeutics are used as a standard treatment regimen for schizophrenia. It helps in reversing the low levels of dopamine and serotonin, thereby improving the patient's condition.

Schizophrenia Therapeutics Market contains market size and forecasts of Schizophrenia Therapeutics in Global, including the following market information:

• Global Schizophrenia Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Schizophrenia Therapeutics market was valued at 10100 million in 2021 and is projected to reach US$ 11340 million by 2028, at a CAGR of 1.7% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

First-Generation Antipsychotic Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Schizophrenia Therapeutics include AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Alkermes, AbbVie, Amgen and Bristol-Myers Squibb, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Schizophrenia Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Schizophrenia Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Schizophrenia Therapeutics Market Segment Percentages, by Type, 2021 (%)

• First-Generation Antipsychotic Drugs
• Second-Generation Antipsychotic Drugs
• Third-Generation Antipsychotic Drugs

Global Schizophrenia Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Schizophrenia Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Clinics
• Other

Global Schizophrenia Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Schizophrenia Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Schizophrenia Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Schizophrenia Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• AstraZeneca
• Eli Lilly
• GlaxoSmithKline
• Johnson & Johnson
• Alkermes
• AbbVie
• Amgen
• Bristol-Myers Squibb